.png){kind=icon}
.png){kind=icon}
Return
Selpercatinib-induced Redifferentiation and Enhanced Radioiodine Uptake in Radioiodine-refractory Thyroid Cancer: A Case Report
.png){kind=icon}
PRE
AI
Z
Z
L
张
DOI：10.1097/RLU.0000000000006431.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
A 32-year-old woman with metastatic papillary thyroid carcinoma, confirmed to harbor an NCOA4-RET fusion and progressing to radioiodine-refractory status, was initiated on selpercatinib. Following 10 months of treatment, serial thyroglobulin (Tg) measurements and post-therapeutic 131I scans after recombinant human TSH stimulation were performed. The scans demonstrated restored diffuse radioiodine uptake in previously refractory lung metastases, accompanied by a significant decline in Tg levels. This case illustrates that selpercatinib can induce effective redifferentiation in RET-altered radioiodine-refractory thyroid cancer, enabling successful radioiodine therapy.
Keywords:
selpercatinib
redifferentiation
radioiodine-refractory differentiated thyroid cancer
<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">131</sup>I therapy
RET fusion
Journal
IF:
9.6
Papers:
1.1W
Citations:
6.9K
Organization
No organization information available
Cited Papers